IceCure Medical Appoints Meir Peleg as CFO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy ICCM?
IceCure Medical appointed Meir Peleg as its CFO, effective May 17. Meir Peleg combines a software engineering background with over 20 years of financial leadership, having previously served as a strategic partner to CEOs and boards. In addition, IceCure plans to appoint Richard Fine in Q2 as the company's Medical Director to lead breast indications. Fine is a breast surgical oncologist and Director of the Breast Program at the Margaret West Comprehensive Breast Center at West Cancer Center & Research Institute in Germantown, Tennessee. The company has initiated a search for a new Chief Technology Officer. Naum Muchnik, IceCure's VP of R&D and Engineering, will be departing his role effective April 12.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICCM
Wall Street analysts forecast ICCM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.301
Low
3.00
Averages
3.00
High
3.00
Current: 0.301
Low
3.00
Averages
3.00
High
3.00
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IceCure Medical Secures $4M in Direct Offering
- Funding Size: IceCure Medical has entered into agreements with healthcare-focused institutional investors to sell 8 million ordinary shares at $0.50 each, with gross proceeds expected to be around $4 million, aimed at strengthening the company's capital base for future growth.
- Warrant Issuance: In this private placement, the company plans to issue Series B and Series C warrants covering up to 8 million shares each, with an exercise price of $0.55 per share, where Series B warrants will expire in five years and Series C in one year, enhancing investor participation incentives.
- Transaction Arrangement: The offering is expected to close on or about March 27, 2026, with Alliance Global Partners acting as the sole placement agent, ensuring a smooth transaction process and boosting market confidence.
- Market Reaction: Despite the financing plan aiding liquidity, IceCure Medical's shares fell by 3.43%, reflecting market concerns over the company's future profitability, which may impact investor confidence.
See More
IceCure Medical Reports Positive Results for ProSense® in Small Renal Masses
- Clinical Trial Results: The ICESECRET trial demonstrated an impressive 89.4% recurrence-free rate for patients with tumors ≤3 cm and no prior kidney cancer at a median follow-up of four years, while the overall study population showed an 83.9% recurrence-free rate, indicating the effectiveness and durability of ProSense® in treating small renal masses.
- Patient Participation: A total of 114 patients were enrolled, with 112 evaluated at the median follow-up of four years; notably, 12 patients underwent a second cryoablation procedure at a mean of 1.73±1.2 years, showcasing the sustained efficacy and good tolerability of the treatment.
- Market Potential: With kidney cancer cases projected to exceed 80,000 new diagnoses in the U.S. alone by 2025, the findings from IceCure's study may drive broader commercial adoption of ProSense® in approved markets, addressing the urgent need for minimally invasive treatment options.
- Future Outlook: Full study results are set to be presented at the European Conference on Interventional Oncology in Basel, Switzerland, in April 2026, as IceCure aims to further solidify ProSense® as an effective treatment option for patients with small renal masses through these positive findings.
See More
ICECURE MEDICAL LTD Reports 89.4% Tumor Recurrence-Free Rate for Tumors ≤3 CM and 83.9% for General Population After 4 Years
- Recurrence-Free Rate: The study reports an 89.4% recurrence-free rate for tumors measuring 3 cm or less.
- General Population Statistics: The recurrence-free rate for the general population stands at 83.9% after four years.
See More
IceCure Medical Appoints New CFO to Support Growth
- Executive Appointment: IceCure Medical has appointed Meir Peleg as Chief Financial Officer, effective May 17, bringing over 20 years of financial leadership experience from Nasdaq-listed companies, which is expected to enhance the company's financial management capabilities.
- FDA Approval Boost: Following the U.S. FDA clearance for ProSense in low-risk breast cancer, the company is gaining significant momentum, and the recommendation from the American Society of Breast Surgeons is likely to enhance product acceptance and drive sales growth.
- Future Personnel Plans: IceCure intends to appoint Richard Fine as Medical Director in the second quarter of 2026 to support its breast cancer clinical and educational initiatives, indicating the company's commitment to improving the quality of medical services.
- Leadership Transition: Vice President of R&D and Engineering Naum Muchnik will depart effective April 12, as the company initiates a search for a new Chief Technology Officer, reflecting a strategic adjustment in the technology leadership to meet future development needs.
See More
IceCure Medical Appoints New CFO and Medical Director
- Executive Appointment: IceCure Medical announced the appointment of Meir Peleg as CFO, effective May 17, 2026, aimed at strengthening the company's financial management and strategic execution capabilities.
- Medical Director Appointment: The company plans to appoint Richard E. Fine as Medical Director in Q2 2026 to lead breast-related initiatives, supporting the FDA-approved ChoICE study to enhance clinical applications of breast cryoablation technology.
- Leadership Transition: IceCure is searching for a new Chief Technology Officer as current VP Naum Muchnik will depart on April 12, 2026, indicating ongoing adjustments and optimizations in the company's technology strategy.
- Financial Performance: IceCure Medical reported a GAAP EPS of -$0.24 and revenue of $3.38 million, reflecting financial challenges, while the stock rose 5.08% in pre-market trading to $0.6699.
See More
IceCure Appoints New CFO and Medical Director
- Executive Appointment: IceCure has announced the appointment of Meir Peleg as Chief Financial Officer, effective May 17, 2026, bringing over 20 years of financial leadership experience from Nasdaq-listed companies, which is expected to enhance the company's commercial growth in the U.S. and globally.
- Product Momentum: Following FDA clearance for ProSense® in low-risk breast cancer, IceCure is experiencing strong commercial momentum in the U.S. market, and Peleg's addition is anticipated to strengthen the company's financial infrastructure to support global adoption of ProSense®.
- Medical Director Appointment: IceCure plans to appoint Dr. Richard E. Fine as Medical Director in the second quarter of 2026, who will lead clinical and educational initiatives in breast cryoablation, further solidifying the company's leadership in this field.
- CTO Search: IceCure is initiating a search for a new Chief Technology Officer as current VP of R&D and Engineering Naum Muchnik will depart on April 12, 2026, aiming to enhance the company's technological strategy and development direction.
See More
IceCure Medical Secures $4M in Direct Offering
- Funding Size: IceCure Medical has entered into agreements with healthcare-focused institutional investors to sell 8 million ordinary shares at $0.50 each, with gross proceeds expected to be around $4 million, aimed at strengthening the company's capital base for future growth.
- Warrant Issuance: In this private placement, the company plans to issue Series B and Series C warrants covering up to 8 million shares each, with an exercise price of $0.55 per share, where Series B warrants will expire in five years and Series C in one year, enhancing investor participation incentives.
- Transaction Arrangement: The offering is expected to close on or about March 27, 2026, with Alliance Global Partners acting as the sole placement agent, ensuring a smooth transaction process and boosting market confidence.
- Market Reaction: Despite the financing plan aiding liquidity, IceCure Medical's shares fell by 3.43%, reflecting market concerns over the company's future profitability, which may impact investor confidence.
See More
IceCure Medical Reports Positive Results for ProSense® in Small Renal Masses
- Clinical Trial Results: The ICESECRET trial demonstrated an impressive 89.4% recurrence-free rate for patients with tumors ≤3 cm and no prior kidney cancer at a median follow-up of four years, while the overall study population showed an 83.9% recurrence-free rate, indicating the effectiveness and durability of ProSense® in treating small renal masses.
- Patient Participation: A total of 114 patients were enrolled, with 112 evaluated at the median follow-up of four years; notably, 12 patients underwent a second cryoablation procedure at a mean of 1.73±1.2 years, showcasing the sustained efficacy and good tolerability of the treatment.
- Market Potential: With kidney cancer cases projected to exceed 80,000 new diagnoses in the U.S. alone by 2025, the findings from IceCure's study may drive broader commercial adoption of ProSense® in approved markets, addressing the urgent need for minimally invasive treatment options.
- Future Outlook: Full study results are set to be presented at the European Conference on Interventional Oncology in Basel, Switzerland, in April 2026, as IceCure aims to further solidify ProSense® as an effective treatment option for patients with small renal masses through these positive findings.
See More
ICECURE MEDICAL LTD Reports 89.4% Tumor Recurrence-Free Rate for Tumors ≤3 CM and 83.9% for General Population After 4 Years
- Recurrence-Free Rate: The study reports an 89.4% recurrence-free rate for tumors measuring 3 cm or less.
- General Population Statistics: The recurrence-free rate for the general population stands at 83.9% after four years.
See More
IceCure Medical Appoints New CFO to Support Growth
- Executive Appointment: IceCure Medical has appointed Meir Peleg as Chief Financial Officer, effective May 17, bringing over 20 years of financial leadership experience from Nasdaq-listed companies, which is expected to enhance the company's financial management capabilities.
- FDA Approval Boost: Following the U.S. FDA clearance for ProSense in low-risk breast cancer, the company is gaining significant momentum, and the recommendation from the American Society of Breast Surgeons is likely to enhance product acceptance and drive sales growth.
- Future Personnel Plans: IceCure intends to appoint Richard Fine as Medical Director in the second quarter of 2026 to support its breast cancer clinical and educational initiatives, indicating the company's commitment to improving the quality of medical services.
- Leadership Transition: Vice President of R&D and Engineering Naum Muchnik will depart effective April 12, as the company initiates a search for a new Chief Technology Officer, reflecting a strategic adjustment in the technology leadership to meet future development needs.
See More
IceCure Medical Appoints New CFO and Medical Director
- Executive Appointment: IceCure Medical announced the appointment of Meir Peleg as CFO, effective May 17, 2026, aimed at strengthening the company's financial management and strategic execution capabilities.
- Medical Director Appointment: The company plans to appoint Richard E. Fine as Medical Director in Q2 2026 to lead breast-related initiatives, supporting the FDA-approved ChoICE study to enhance clinical applications of breast cryoablation technology.
- Leadership Transition: IceCure is searching for a new Chief Technology Officer as current VP Naum Muchnik will depart on April 12, 2026, indicating ongoing adjustments and optimizations in the company's technology strategy.
- Financial Performance: IceCure Medical reported a GAAP EPS of -$0.24 and revenue of $3.38 million, reflecting financial challenges, while the stock rose 5.08% in pre-market trading to $0.6699.
See More
IceCure Appoints New CFO and Medical Director
- Executive Appointment: IceCure has announced the appointment of Meir Peleg as Chief Financial Officer, effective May 17, 2026, bringing over 20 years of financial leadership experience from Nasdaq-listed companies, which is expected to enhance the company's commercial growth in the U.S. and globally.
- Product Momentum: Following FDA clearance for ProSense® in low-risk breast cancer, IceCure is experiencing strong commercial momentum in the U.S. market, and Peleg's addition is anticipated to strengthen the company's financial infrastructure to support global adoption of ProSense®.
- Medical Director Appointment: IceCure plans to appoint Dr. Richard E. Fine as Medical Director in the second quarter of 2026, who will lead clinical and educational initiatives in breast cryoablation, further solidifying the company's leadership in this field.
- CTO Search: IceCure is initiating a search for a new Chief Technology Officer as current VP of R&D and Engineering Naum Muchnik will depart on April 12, 2026, aiming to enhance the company's technological strategy and development direction.
See More
